Potential solutions to enhance KRAS-targeted TCR-T therapy include multi-antigen targeting to address tumor heterogeneity, universal TCR platforms for broader patient applicability, and advanced gene editing techniques like CRISPR/Cas9 to improve TCR specificity and reduce off-target effects. This evidence concerns the gene KRAS and neoplasm.